• HOXC8 Suppresses Pyroptosis in NSCLC via Caspase-1 Regulatio

  2026-04-27

  This study unveils a new tumorigenic mechanism in non-small cell lung carcinoma (NSCLC), where HOXC8 suppresses pyroptotic cell death by downregulating caspase-1 expression. These findings link HOXC8-mediated transcriptional control to pyroptosis regulation, revealing novel targets for cancer research and inflammasome activation studies.

• Cy3 Goat Anti-Human IgG (H+L) Antibody: Workflow-Driven Adva

  2026-04-27

  The Cy3 Goat Anti-Human IgG (H+L) Antibody from APExBIO transforms immunofluorescence, immunohistochemistry, flow cytometry, and ELISA with powerful, reproducible signal amplification and flexibility. Explore best practices, troubleshooting, and protocol innovations that enable sensitive human IgG detection across research domains.

• Structural Insights into Gepotidacin vs. Fluoroquinolone Act

  2026-04-26

  This study elucidates the unique mechanism of gepotidacin, a novel bacterial topoisomerase inhibitor, in targeting Staphylococcus aureus DNA gyrase. By contrasting its single-stranded DNA cleavage profile with double-stranded breaks induced by fluoroquinolone antibiotics, the research advances our understanding of resistance mechanisms and informs antibiotic toxicity research.

• Latrunculin B in Translational Science: Mechanism, Strategy,

  2026-04-25

  Explore how Latrunculin B, a cell-permeable actin polymerization inhibitor from APExBIO, enables precision disruption of the actin cytoskeleton in translational research. This article synthesizes mechanistic insights, compares competitive landscape data, and delivers actionable guidance for maximizing impact in cytoskeletal and disease-modeling studies, while critically examining cross-domain relevance and experimental limitations.

• Homoharringtonine Rapidly Clears SARS-CoV-2: Molecular Evide

  2026-04-24

  This study demonstrates that homoharringtonine, a cytotoxic alkaloid, achieves rapid and robust clearance of SARS-CoV-2 in both animal models and human patients by targeting protein synthesis in infected cells. These findings highlight its potential as a first-line intervention for future coronavirus outbreaks, while also clarifying protocol parameters and limitations for translational research.

• Palonosetron Hydrochloride: Advances in Preventing Chemother

  2026-04-24

  Ruhlmann and Herrstedt’s review critically examines palonosetron hydrochloride, a next-generation 5-HT3 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV). Their synthesis highlights palonosetron’s unique pharmacological features, clinical efficacy, and comparative advantages over first-generation agents—offering researchers insight into translational strategies for antiemetic regimens.

• Tankyrase Inhibition Suppresses HCC via Hippo Pathway Modula

  2026-04-23

  Jia et al. (2017) demonstrate that selective tankyrase 1/2 inhibitors, including G007-LK, suppress hepatocellular carcinoma (HCC) cell proliferation through modulation of the Hippo-YAP signaling cascade. The study reveals mechanistic links between tankyrase activity, YAP regulation, and potential therapeutic strategies for HCC.

• Glabridin-Gold(I) Complex Enhances Antitumor Immunity via Tr

  2026-04-23

  A recent study introduces a glabridin-gold(I) complex (6d) that targets TrxR and MAPK pathways, driving immunogenicity and mitigating immunosuppression in liver cancer models. This dual-action strategy advances the mechanistic understanding of metal-based immunomodulators and highlights implications for combinatorial cancer immunotherapy.

• N6-Methyl-dATP: Dissecting Epigenetic Fidelity and Mechanism

  2026-04-22

  Explore the unique mechanistic insights N6-Methyl-dATP brings to epigenetic nucleotide research and DNA replication fidelity studies. This article delivers an in-depth analysis of methylation effects in acute myeloid leukemia (AML), surpassing standard assay discussions with practical, evidence-based parameters.

• PAD4-IN-2 TFA: Precision NET Inhibition in Tumor Research

  2026-04-22

  PAD4-IN-2 TFA (Compound 5i TFA) delivers highly selective, tumor-targeted inhibition of histone H3 citrullination and neutrophil extracellular trap (NET) formation, empowering researchers to dissect and modulate the tumor immune microenvironment with unprecedented specificity. This article translates bench-validated workflows and troubleshooting insights into actionable guidance for maximizing the translational impact of APExBIO’s PAD4-IN-2 TFA in advanced cancer research.

• Redefining Protease Inhibition for Translational Precision

  2026-04-21

  Explore how the Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO) from APExBIO sets a new standard for protein integrity in translational research. This article delivers mechanistic clarity, evidence-based protocol guidance, and strategic insight into the evolving landscape of protease inhibition—bridging bench discovery with clinical promise.

• Adenosine Triphosphate (ATP): Structure, Function & Research

  2026-04-21

  Adenosine Triphosphate (ATP) is the universal energy carrier essential for cellular metabolism and signaling. High-purity ATP enables rigorous studies of enzyme regulation and purinergic signaling in biomedical research. This article details ATP’s structure, mechanisms, and validated research benchmarks.

• Eltanexor (KPT-8602): Transforming Nuclear Export Inhibition

  2026-04-20

  Eltanexor (KPT-8602) stands out as a potent, orally bioavailable inhibitor of XPO1, enabling targeted disruption of nuclear export in cancer models. Its robust efficacy in modulating Wnt/β-catenin signaling and superior tolerability profile make it a premier tool for applied studies in leukemia and colorectal cancer research.

• Tamoxifen as a Selective Estrogen Receptor Modulator in Rese

  2026-04-20

  Tamoxifen’s dual function as a selective estrogen receptor modulator and CreER gene knockout inducer sets it apart for precision genetic and oncology studies. This guide synthesizes cutting-edge protocols, troubleshooting insights, and new findings on developmental effects, empowering researchers to maximize reliability and safety.

• XAV-939: Potent Tankyrase Inhibitor for Wnt/β-Catenin Resear

  2026-04-19

  XAV-939 (NVP-XAV939) is a nanomolar tankyrase 1/2 inhibitor that suppresses Wnt/β-catenin signaling by axin stabilization and β-catenin degradation. It is widely used as a tool compound to dissect osteogenic differentiation, cancer, and fibrosis pathways. APExBIO supplies XAV-939 for reproducible research applications.

11238 records 1/750 page Next 12345 下5页 Last page